Last reviewed · How we verify

Breast cancer (for palliation only) in appropriately selected women and men with metastatic disease — Treatment Landscape & Competitive Intelligence

Breast cancer (for palliation only) in appropriately selected women and men with metastatic disease (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Breast cancer (for palliation only) in appropriately selected women and men with metastatic disease, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Menest Estrogens, Esterified Pfizer Inc. Estrogen Estrogen receptor

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Pfizer Inc. · 1 drug in Breast cancer (for palliation only) in appropriately selected women and men with metastatic disease

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Breast cancer (for palliation only) in appropriately selected women and men with metastatic disease:

Cite this brief

Drug Landscape (2026). Breast cancer (for palliation only) in appropriately selected women and men with metastatic disease — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/breast-cancer-for-palliation-only-in-appropriately-selected-women-and-men-with-metastatic-disease. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing